F Blackhall
F Blackhall
University of Manchester
Verified email at christie.nhs.uk
Title
Cited by
Cited by
Year
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ...
New England Journal of Medicine 368 (25), 2385-2394, 2013
33442013
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...
N Engl j Med 371, 2167-2177, 2014
25932014
Tracking the evolution of non–small-cell lung cancer
M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, TBK Watkins, ...
New England Journal of Medicine 376 (22), 2109-2121, 2017
12382017
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ...
Nature 545 (7655), 446-451, 2017
8472017
Evaluation and prognostic significance of circulating tumor cells in patients with non–small-cell lung cancer
MG Krebs, R Sloane, L Priest, L Lancashire, JM Hou, A Greystoke, ...
Journal of clinical oncology 29 (12), 1556-1563, 2011
8432011
Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer
JM Hou, MG Krebs, L Lancashire, R Sloane, A Backen, RK Swain, ...
J Clin Oncol 30 (5), 525-532, 2012
7432012
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
CL Hodgkinson, CJ Morrow, Y Li, RL Metcalf, DG Rothwell, F Trapani, ...
Nature medicine 20 (8), 897-903, 2014
5812014
Molecular analysis of circulating tumour cells—biology and biomarkers
MG Krebs, RL Metcalf, L Carter, G Brady, FH Blackhall, C Dive
Nature reviews Clinical oncology 11 (3), 129, 2014
5332014
Allele-specific HLA loss and immune escape in lung cancer evolution
N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ...
Cell 171 (6), 1259-1271. e11, 2017
5012017
Circulating tumor cells as a window on metastasis biology in lung cancer
JM Hou, M Krebs, T Ward, R Sloane, L Priest, A Hughes, G Clack, ...
The American journal of pathology 178 (3), 989-996, 2011
4492011
Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches
MG Krebs, JM Hou, R Sloane, L Lancashire, L Priest, D Nonaka, TH Ward, ...
Journal of thoracic oncology 7 (2), 306-315, 2012
4212012
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component.
JC Yang, MJ Ahn, DW Kim, SS Ramalingam, LV Sequist, S Wc, SW Kim, ...
3782017
Three-gene prognostic classifier for early-stage non–small-cell lung cancer
SK Lau, PC Boutros, M Pintilie, FH Blackhall, CQ Zhu, D Strumpf, ...
Journal of Clinical Oncology 25 (35), 5562-5569, 2007
2852007
K-ras mutations in non-small-cell lung carcinoma: a review
S Aviel-Ronen, FH Blackhall, FA Shepherd, MS Tsao
Clinical lung cancer 8 (1), 30-38, 2006
2782006
Vandetanib plus pemetrexed for the second-line treatment of advanced non–small-cell lung cancer: A randomized, double-blind phase III trial
RH De Boer, Ó Arrieta, CH Yang, M Gottfried, V Chan, J Raats, ...
Journal of Clinical Oncology 29 (8), 1067-1074, 2011
2692011
Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.
L Crino, D Kim, GJ Riely, PA Janne, FH Blackhall, DR Camidge, V Hirsh, ...
Journal of Clinical Oncology 29 (15_suppl), 7514-7514, 2011
2662011
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan–human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non …
SS Ramalingam, F Blackhall, M Krzakowski, CH Barrios, K Park, I Bover, ...
Journal of clinical oncology 30 (27), 3337, 2012
2632012
Fc effector function contributes to the activity of human anti-CTLA-4 antibodies
FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ...
Cancer cell 33 (4), 649-663. e4, 2018
2592018
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
C Faivre-Finn, M Snee, L Ashcroft, W Appel, F Barlesi, A Bhatnagar, ...
The Lancet Oncology 18 (8), 1116-1125, 2017
2512017
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy
JM Hou, A Greystoke, L Lancashire, J Cummings, T Ward, R Board, ...
The American journal of pathology 175 (2), 808-816, 2009
2492009
The system can't perform the operation now. Try again later.
Articles 1–20